Potentials of drug therapy for metastatic/recurrent cervical cancer


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The primary goal of drug therapy for metastatic cervical cancer (CC) in patients with a persistent/recurrent diagnosis who cannot undergo a radical treatment is the prolongation of life without a significant deterioration in its quality. The article discusses the potentials of modern palliative drug therapy, including various options for chemo-, targeted, and immunotherapy. Based on the results of a randomized GOG-240 study, doublets: cisplatin 50 mg/m2 on day 1+paclitaxel 135 or 175 mg/m2 on day 1 or topotecan 0.75 mg/m2on days 1-3+paclitaxel 135 mg/m2 with the addition of bevacizumab 15 mg/kg every 21 days become the standard in the treatment of metastatic and recurrent cervical cancer.

Texto integral

Acesso é fechado

Sobre autores

Elena Ulrikh

Northwestern State Medical University n.a. I.I. Mechnikov; St. Petersburg State Pediatric Medical University

Email: rectorat@szgmu.ru
MD, Professor, Prof. at the Department

T. Semiglazova

Northwestern State Medical University n.a. I.I. Mechnikov

D. Khalimbekova

Northwestern State Medical University n.a. I.I. Mechnikov

O. Smirnova

Northwestern State Medical University n.a. I.I. Mechnikov

D. Ulrikh

St. Petersburg State Pediatric Medical University

A. Urmancheeva

Northwestern State Medical University n.a. I.I. Mechnikov

Bibliografia

  1. Bonomi P., Blessing J.A., Stehman F.B., et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin Oncol. 1985; 3:1079-85.
  2. Monk B.J., Sill M.W., McMeekin D.S., et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin Oncol. 2009;27:4649-55. Doi: 10.1200/ JCO.2009.21.8909.
  3. Kitagawa R., Katsumata N., Shibata T., et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVB, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) J. Clin Oncol. 2012;(Suppl):abstr 5006.
  4. Практические рекомендации по лекарственному лечению злокачественных опухолей. Практические рекомендации по поддерживающей терапии в онкологии (RUSSCO). Под ред. В.М. Моисеенко. М., 2017; спецвыпуск 7(3):58-167.
  5. Monk B.J., Sill M.W., Burger R.A., et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin Oncol. 2009;27:1069-74. doi: 10.1200/JCO.2008.18.9043.
  6. Zighelboim I., Wright J.D., Feng Gaoc F. et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130(1):64-8. Doi: 10.1016/j. ygyno.2013.04.009.
  7. Tewari K.S., Sill M.W., Penson R.T., et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) ational Cancer Institute. Lancet. 2017;390(10103):1654-63. doi: 10.1016/S0140-6736(17)31607-0.
  8. Хохлова. С.В. Место бевацизумаба в лечении больных раком яичников и раком шейки матки. Современная онкология. 2017;1:34-41.
  9. Okawa T., Niibe H., Arai T., et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer. 1993;72:1949-54.
  10. Fujiwara K., Ohashi Y., Ochiai K., et al. Phase III placebo controlled double blind randomized trial of radiation therapy for stage 2B-4A cervical cancer with immunomodulator Z-100: JGOG-DT101 study. J. Clin Oncol. 2013; (Suppl; abstr 5506).
  11. Gunn G.R., Zubair A., Peters C., et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471-79.
  12. Kaufmann A.M., Stern P.L., Rankin E.M., et al. Safety andimmunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676-85.
  13. Ressing M.E., van Driel W.J., Brandt R.M., et al. Detection of T. helper responses, but not of human papillomavirus- specific cytotoxic T. lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 2000;23:255-66.
  14. Kenter G.G., Welters M.J., Valentijn A.R., et al. Phase I. immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin CancerRes. 2008;14:169-77. doi: 10.1158/1078-0432.CCR-07-1881.
  15. Welters M.J., Kenter G.G., Piersma S.J., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-87. doi: 10.1158/1078-0432. CCR-07-1880.
  16. Ferrara A., Nonn M., Sehr P., et al. Dendritic cell-base tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res Clin Oncol. 2003;129:521-30.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies